Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events. Upon completion of this activity, participants should be better able to: Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer; Describe disease